该产品被引用文献
1. Raza S, Rajak S, Upadhyay A, Tewari A, Anthony Sinha R. Current treatment paradigms and emerging therapies for NAFLD/NASH. Front Biosci . 2021;26(2):206-237. Published 2021 Jan 1. doi:10.2741/4892
2. Xu X, Poulsen KL, Wu L, et al. Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH). Signal Transduct Target Ther. 2022;7(1):287. Published 2022 Aug 13. doi:10.1038/s41392-022-01119-3
3. Schuster S, Cabrera D, Arrese M, Feldstein AE. Triggering and resolution of inflammation in NASH. Nat Rev Gastroenterol Hepatol. 2018;15(6):349-364. doi:10.1038/s41575-018-0009-6
4. Tang H, Gamdzyk M, Huang L, et al. Delayed recanalization after MCAO ameliorates ischemic stroke by inhibiting apoptosis via HGF/c-Met/STAT3/Bcl-2 pathway in rats. Exp Neurol. 2020;330:113359. doi:10.1016/j.expneurol.2020.113359
5. Zhou Z, Xu N, Matei N, et al. Sodium butyrate attenuated neuronal apoptosis via GPR41/Gβγ/PI3K/Akt pathway after MCAO in rats. J Cereb Blood Flow Metab. 2021;41(2):267-281. doi:10.1177/0271678X20910533
6. Wang C, Ma Z, Wang Z, et al. Eriodictyol Attenuates MCAO-Induced Brain Injury and Neurological Deficits via Reversing the Autophagy Dysfunction. Front Syst Neurosci. 2021;15:655125. Published 2021 May 26. doi:10.3389/fnsys.2021.655125
